Monopteros Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Monopteros Therapeutics General Information

Description

Developer of inhibitor cells designed to focus on reprogramming regulatory T-cells. The company works on a treatment to reprogram T-cells in the tumor microenvironment to jump-start an immune attack and also provides immunotherapy, which harnesses the power of the immune system to recognize and destroy cancer, enabling cancer patients to have a lasting, life-changing immune response against solid tumors.

Contact Information

Website
www.monopterostx.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Boston, MA
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Boston, MA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Monopteros Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 13-Jul-2025 Completed Out of Business
1. Early Stage VC (Series A) 22-Apr-2021 Completed Clinical Trials - Phase 1
To view Monopteros Therapeutics’s complete valuation and funding history, request access »

Monopteros Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view Monopteros Therapeutics’s complete cap table history, request access »

Monopteros Therapeutics Patents

  • 7

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 1

    Pending

  • Expiring in next 12 mo

Monopteros Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240217961-A1 (s)-mepazine salt forms, process of preparing, and formulations thereof Inactive 05-Mar-2021
WO-2022187568-A1 (s)-mepazine salt forms, process of preparing, and formulations thereof Inactive 05-Mar-2021
EP-4243812-A1 Materials and methods of treating cancer Inactive 12-Nov-2020
US-20230414629-A1 Materials and methods of treating cancer Inactive 12-Nov-2020
WO-2022101676-A1 Materials and methods of treating cancer Inactive 12-Nov-2020 A61K31/41
To view Monopteros Therapeutics’s complete patent history, request access »

Ready to get started?

Request a free trial

Monopteros Therapeutics FAQs

  • When was Monopteros Therapeutics founded?

    Monopteros Therapeutics was founded in 2019.

  • Where is Monopteros Therapeutics headquartered?

    Monopteros Therapeutics is headquartered in Boston, MA.

  • What industry is Monopteros Therapeutics in?

    Monopteros Therapeutics’s primary industry is Drug Discovery.

  • Is Monopteros Therapeutics a private or public company?

    Monopteros Therapeutics is a Private company.

  • What is Monopteros Therapeutics’s current revenue?

    The current revenue for Monopteros Therapeutics is .

  • How much funding has Monopteros Therapeutics raised over time?

    Monopteros Therapeutics has raised $20M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process